Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.54 |
| ▸ | DRD3 | P35462 | 7/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 6/20 | 0.49 |
| ▸ | KDM1B | Q8NB78 | 6/20 | 0.49 |
| ▸ | MAOA | P21397 | 4/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3328391 | 0.88 | HTR6 (0.55) | HTR6CYP11B1CYP11B2DRD3HRH3 | |
| SCHEMBL3325030 | 0.85 | KDM1A (0.62) | HTR6CYP11B1CYP11B2DRD3HRH3 | |
| SCHEMBL3326267 | 0.82 | HTR6 (0.78) | HTR6DRD3HRH3KDM1AKDM1B | |
| SCHEMBL3326162 | 0.75 | HTR6 (0.46) | HTR6DRD3 | |
| SCHEMBL19640868 | 0.72 | AKR1C3 (0.58) | HTR6CYP11B1CYP11B2KDM2BRORC | |
| SCHEMBL20757498 | 0.72 | HTR2C (0.44) | — | |
| SCHEMBL4196434 | 0.71 | BRAF (0.53) | DRD3RORCKCNH2 | |
| Tert-Butyl Formate SCHEMBL27774753 | 0.69 | HTR6 (0.42) | HTR6KDM2B | |
| SCHEMBL25145662 | 0.69 | PKM (0.55) | CYP11B1CYP11B2KDM2B | |
| SCHEMBL21382019 | 0.69 | HCRTR2 (0.41) | DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507469-B2 | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-08-13 | — | — | US | claimed |
| US-20100137280-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-06-03 | — | — | US | claimed |
| CN-101679381-A | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO KG | 2010-03-24 | — | — | CN | claimed |
| US-8507469-B2 | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-08-13 | — | — | US | disclosed |
| US-20100137280-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-06-03 | — | — | US | disclosed |
| CN-101679381-A | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO KG | 2010-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137280-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR4, HTR3C | HTR6 1/4885CYP11B1 482/4885CYP11B2 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.